Upfront Briefing
Europe finally gets its weight-loss pill: the EC waved through oral Wegovy — the first oral GLP-1 cleared for weight management across the bloc — plus a 7.2 mg pen, handing Novo a head start on Lilly's still-pending orforglipron before the cannibalization math even kicks in. Elsewhere, Merck and Kelun's TROP2 ADC notched a second first-line lung win, this time in the PD-L1-negative crowd that usually gets stuck with chemo, while J&J reminded everyone that a $55B "Made in America" pledge comes with a $750M invoice. Erasca, for its part, closed the books on a $632.5M raise — greenshoe and all.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,572.4 |
0.4% |
10.4% |
| Nasdaq 100 |
29,502.6 |
(0.3%) |
17.0% |
| Russell 2000 |
2,976.3 |
0.4% |
18.7% |
| Healthcare (XLV) |
158.3 |
0.0% |
1.8% |
| Biotech (XBI) |
156.2 |
0.5% |
28.6% |
| Nasdaq Biotech (NBI) |
6,562.0 |
0.7% |
15.0% |
| Clinical Trials (BBC) |
51.9 |
0.5% |
37.8% |
|
- Biotech again outran defensive healthcare — XBI +0.5% and NBI +0.7% against a flat XLV — as Novo Nordisk's EU oral-Wegovy clearance and Celcuity's first-in-class Revtorpyk approval headlined a heavy biopharma news day.
- The broad tape rose on a softer-than-expected June PPI (headline down 0.3%), reinforcing the prior session's cooling-CPI read that the Fed likely holds this month; the megacap-heavy Nasdaq 100 slipped 0.3% as chip names (Micron off 8%) sold off and fresh U.S.–Iran strikes kept oil bid.
- Market data: U.S. cash close Wednesday, 15 July 2026.
The Big 3
|
1
|
EU clears oral Wegovy and a 7.2 mg pen for Novo Nordisk
|
- The European Commission approved Wegovy pill (oral semaglutide 25 mg) as the first oral GLP-1 for weight management in the EU, and separately cleared the higher-dose 7.2 mg single-dose pen, effective across all 27 member states.
- Why it matters: The nod hands Novo two obesity levers at once: an oral route (about 17% mean weight loss in OASIS 4 vs 3% on placebo, with roughly one in three hitting 20%+) that reaches needle-averse patients, plus a 7.2 mg pen (21% loss) for in-brand dose escalation. It lands ahead of Lilly's oral orforglipron, which has yet to clear the EU pathway, extending Novo's first-mover grip across the bloc. The pill logged more than 1M US starts within four months of its January launch, so the readthrough is commercial as much as regulatory; European scripts should begin shifting off injection-only. Pricing and launch sequencing are the variables to watch as the two franchises' cannibalization math gets tested.
- Source: Reuters
- More: Novo Nordisk; Seeking Alpha;
|
|
2
|
Merck/Kelun sac-TMT hits Phase 3 goal in PD-L1-negative lung cancer
|
- The TROP2 ADC sacituzumab tirumotecan plus Keytruda met its primary PFS endpoint at a prespecified interim analysis in first-line PD-L1-negative non-squamous NSCLC (OptiTROP-Lung06) — a chemo-free combo in a population that normally defaults to chemotherapy.
- Why it matters: This is the second first-line NSCLC win for the Merck-licensed TROP2 ADC, now in the hardest-to-treat PD-L1-negative segment where checkpoint monotherapy fails; the sister OptiTROP-Lung05 study (PD-L1-positive) cut progression risk 65% versus Keytruda alone. A chemo-free ADC-plus-IO regimen that works regardless of PD-L1 status reshapes Merck's post-Keytruda-LOE roadmap and pressures rival TROP2 programs, notably AstraZeneca/Daiichi's Dato-DXd. Two caveats temper it: overall survival was immature at the readout, and the trial is China-run and China-sourced, keeping COINS Act exposure and NMPA-to-FDA translatability in view.
-
Source:
Targeted Oncology
- More: Kelun-Biotech; CancerNetwork;
|
| 3 | J&J to take up to $750M pharma supply chain charge |
- J&J said it expects up to $750M in costs to restructure its pharmaceutical supply chain and exit factories, following its previously announced $55B U.S. manufacturing commitment.
- Why it matters: The up-to-$750M charge covers decommissioning, asset impairments and site exits, with $200M already booked in Q2 and the balance running through FY2029. It converts J&J's $55B onshoring pledge into a real P&L line and signals that the tariff-driven reshoring wave carries near-term margin cost, a template peers like AbbVie and Novartis will be measured against. J&J cushioned the hit by raising full-year guidance on 6.6% Q2 sales growth and reiterating its first-ever target of $100B-plus in annual revenue, keeping the debate on capital efficiency rather than balance-sheet strain.
- Source: Endpoints
- More: BioSpace
|
Everything Else that broke
- FDA said two recent journal articles did not constitute agency policy, dialing back journal-based rulemaking risk. — Endpoints
- Celcuity's first-in-class Revtorpyk (gedatolisib) cleared FDA in HR+/HER2-, PIK3CA-wild-type breast cancer, but a late-Q3 launch delay and tolerability concerns knocked shares about 16% on the session. — BioPharma Dive
- J&J scrapped its geographic-atrophy gene therapy JNJ-1887 after topline Phase 2b Parasol data, extending an ophthalmology-and-cell-therapy purge that also swept out two CAR-Ts and a MeiraGTx-bound eye asset. — Fierce Biotech
- Senators pressed the CDC nominee over vaccine interference, keeping policy noise alive around immunization oversight. — Endpoints
- AAIC spotlighted Alzheimer's blood-test research and cognitive-decline prediction, though still at conference-stage rather than commercial-stage. — PR
- 10x Genomics set August 6 for Q2 results, putting a clean catalyst on the tools calendar. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lilly made an undisclosed equity investment in Oura to support patients using its GLP-1 medicines. — STAT
VC / Private Financings
- AdvanCell raised an oversubscribed $315M Series D co-led by Ally Bridge Group and Alpha Wave, with Bain Capital Life Sciences, Lilly, Sanofi Ventures and Fidelity among others, to move Pb-212 alpha-therapy ADVC001 toward Phase 3 in metastatic prostate cancer — a Pluvicto challenger. — Fierce Biotech
- Draig Therapeutics closed an oversubscribed $65M Series B led by Deep Track Capital, joined by Janus Henderson, Marshall Wace, British Business Bank and Jefferson Life Sciences, to push AMPA-receptor PAM DT-101 through Phase 2 in major depressive disorder. — Endpoints
IPOs / Follow-Ons
- Braveheart Bio filed to list on Nasdaq (BRVE) to fund Phase 3 of BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy licensed from China's Hengrui, squaring up against BMS's Camzyos and Cytokinetics' Myqorzo. — Fierce Biotech
- Attovia Therapeutics filed for an IPO to advance IL-31 fusion protein ATTO-1310 (65% Week-4 itch response in Phase 1b) into Phase 2 in atopic dermatitis and chronic pruritus, taking aim at Dupixent and Galderma's Nemluvio. — Fierce Biotech
- Erasca closed its upsized common-stock follow-on at $17.50, taking gross proceeds to $632.5M after the underwriters' full greenshoe. — BioWorld
Academic Corner - Obinutuzumab plus standard therapy beat placebo over 52 weeks in active SLE without advanced lupus nephritis. — NEJM
- A phase 1 trial of a SOD1-targeting oligonucleotide-siRNA conjugate showed a favorable safety profile in six ALS patients. — Nature Medicine
- A phase 1b Alzheimer's trial of a short-lived anti-PD-L1 antibody was safe and well tolerated, with biomarker trends. — Nature Medicine
|
